Potential Predictors of Biological Therapy Intensification in Moderate-To-Severe Hidradenitis Suppurativa: A Multicentre Study.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Melgosa Ramos F.J.
  • García Ruiz R.

Abstract

Moderate-to-severe hidradenitis suppurativa (HS) is a debilitating disease that often requires biological therapy. Despite the effectiveness of approved doses, some patients experience partial or loss of response over time, leading to the need for dose intensification. This retrospective multicentre study aimed to identify predictors of biological therapy intensification in HS patients. The results showed that prior use of biological treatments and biosimilar adalimumab were significant predictors of intensification, suggesting closer monitoring may be needed for certain patient profiles to optimise treatment outcomes.

© 2025 The Australasian College of Dermatologists.

Datos de la publicación

ISSN/ISSNe:
0004-8380, 1440-0960

AUSTRALASIAN JOURNAL OF DERMATOLOGY  WILEY

Tipo:
Article
Páginas:
35-38
PubMed:
39777724
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
0,639 SCImago ℠
Cuartil:
Q2 SCImago ℠

Citas Recibidas en Web of Science: 1

Citas Recibidas en Scopus: 1

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • disease modification; hidradenitis suppurativa; intensification; window of opportunity

Cita

Compartir